- The author estimates that in 2016, there were 312,000 incident cases of thyroid cancer worldwide, and forecasts that number to increase to 342,000 incident cases by 2025.
- Asia is estimated to have the highest disease incidence, while Oceania has the lowest incidence. The approved drugs in the thyroid cancer space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with one product being available in an intramuscular formulation.
- The majority of industry-sponsored drugs in active clinical development for thyroid cancer are in Phase II, with only one drug in Phase III.
- Therapies in mid-to-late-stage development for thyroid cancer focus on targets such as mitogen-activated ERK kinase, microtubules (tubulin), carcinoembryonic antigen, Raf kinase, tumor necrosis factor-alpha, RET, and ErbB3/HER3. Half of the drugs in mid-to-late-stage development are administered via the oral route, with the remainder being intravenous or subcutaneous formulations.
- High-impact upcoming events for drugs in the thyroid cancer space comprise topline Phase III results and Phase II results for Selumetinib and GI-6207, respectively.
- There have been 11 licensing and asset acquisition activity deals involving thyroid cancer drugs during 2013-18. The largest deal was the $1,119m exclusive licensing agreement in February 2016 between Exelixis and Ipsen for the commercialization and further development of Cometriq (cabozantinib).
- Nexavar’s sales ranked highest among drugs available for thyroid cancer during 2012-17. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for thyroid cancer have been in the early and mid-phases of development, with 92% of trials in Phase I-II, and only 8% in Phase III-IV.
- The US has a substantial lead in the number of thyroid cancer clinical trials globally. France leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the thyroid cancer space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for thyroid cancer, with 27 completed trials.
- Novartis leads industry sponsors with the highest number of clinical trials for thyroid cancer, followed by Pfizer and GlaxoSmithKline.
Radioactive iodine (RAI) therapy
Thyroid hormone therapy
External beam radiation therapy
KEY UPCOMING EVENTS
LICENSING AND ASSET ACQUISITION DEALS
NanoCarrier Gets Japanese Rights To VBL Cancer Gene Therapy
Takeda Adds Exelixis Arrow To Oncology Quiver
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
List of Figures
Figure 1: Trends in incident cases of thyroid cancer, 2016-25
Figure 2: Pipeline drugs for thyroid cancer in the US
Figure 3: Pipeline drugs for thyroid cancer, by company
Figure 4: Pipeline drugs for thyroid cancer, by drug type
Figure 5: Pipeline drugs for thyroid cancer, by classifications
Figure 6: Key upcoming events in thyroid cancer
Figure 7: Licensing and asset acquisition deals in thyroid cancer
Figure 8: Parent patents in thyroid cancer
Figure 9: Clinical trials in thyroid cancer
Figure 10: Top 10 drugs for clinical trials in thyroid cancer
Figure 11: Top 10 companies for clinical trials in thyroid cancer
Figure 12: Trial locations in thyroid cancer
Figure 13: Thyroid cancer sponsors, by status
Figure 14: Thyroid cancer sponsors, by phase
List of Tables
Table 1: Incident cases of thyroid cancer, 2016-25
Table 2: Marketed drugs for thyroid cancer
Table 3: Approvals by country for thyroid cancer
Table 4: Pipeline drugs for thyroid cancer in the US
Table 5: Historical global sales, by drug ($m), 2012-17
Table 6: Forecasted global sales, by drug ($m), 2018-22